Table 1:

Baseline characteristics of participants assessed at either 3 or 12 months by treatment group

	Placebo n=107	Haloperidol n=97	Ziprasidone n=112
Age (years)	59 [50–65]	57 [48–64]	57 [48–66]
Female sex	47 (44)	40 (41)	46 (41)
Race
White	86 (80)	82 (85)	89 (80)
Black or other race(s)	21 (20)	15 (16)	23 (21)
Short-form IQCODE	3.0 [3.0–3.2]	3.0 [3.0–3.2]	3.0 [3.0–3.3]
Charlson Comorbidity Index	2 [1–3]	1 [0–3]	2 [1–3]
Received antipsychotic treatment
Before admission	4 (4)	5 (5)	9 (8)
Between admission and randomization	8 (8)	11 (11)	10 (9)
Admitting diagnosis
Acute respiratory distress syndrome	22 (21)	16 (17)	22 (20)
Sepsis	18 (17)	20 (21)	16 (14)
Airway protection	35 (33)	22 (23)	31 (28)
COPD, asthma, or other pulmonary disorder	11 (10)	13 (13)	14 (13)
Surgery	8 (8)	11 (11)	13 (12)
CHF, myocardial infarction, or arrhythmia	3 (3)	4 (4)	4 (4)
Cirrhosis or liver failure	3 (3)	2 (2)	0 (0)
Seizures or neurological disease	1 (1)	2 (2)	0 (0)
Other	6 (6)	7 (7)	12 (11)
Admitted to the surgical ICU	33 (31)	32 (33)	33 (30)
APACHE II at ICU admission	29 [23–32]	27 [22–33]	28 [23–34]
SOFA at randomization	11 [8–14]	11 [8–13]	10 [7–13]
Received assisted ventilation before randomization
Invasive	100 (94)	94 (97)	110 (98)
Noninvasive	3 (3)	2 (2)	2 (2)
Shock before randomization	32 (30)	22 (23)	28 (25)
Days from ICU admission to randomization	2.0 [1.5–3.1]	2.1 [1.6–3.2]	2.6 [1.7–3.4]

Data are median [IQR] or n (%). APACHE=Acute Physiologic Assessment and Chronic Health Evaluation. ARDS=acute respiratory distress syndrome. CHF=congestive heart failure. COPD=chronic obstructive pulmonary disease. ICU=intensive care unit. IQCODE=Informant Questionnaire on Cognitive Decline in the Elderly. SOFA=Sequential Organ Failure Assessment.